Quest Diagnostics Incorporated with ticker code (DGX) have now 15 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between 165 and 140 and has a mean target at $147.60. Now with the previous closing price of $131.62 and the analysts are correct then we can expect a percentage increase in value of 12.1%. Also worth taking note is the 50 day moving average now sits at $137.99 and the 200 day MA is $139.82. The total market capitalization for the company now stands at 14.68B. The stock price is currently at: 131.09 USD
The potential market cap would be $16,465,956,252 based on the market consensus.
The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of 19.19, revenue per share of 84.05 and a 6.44% return on assets.
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, independent delivery networks (IDNs), health plans, employers, consumers, and accountable care organizations (ACOs). It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology business, which offers solutions for healthcare providers. The Company’s services are primarily provided under the Quest Diagnostics brand and also provide services under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
